Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of JNJ-37822681 in healthy male volunteers
NL-OMON30850Active, not recruiting
- Sponsor
- Johnson & Johnson
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of JNJ-37822681 in psychosis, sponsored by Johnson & Johnson. Primary endpoints: Safety and tolerability, Pharmacokinetics of JNJ-37822681 and metabolites and 10 more. Started May 2007; status: active, not recruiting.
02
Drugs
JNJ-37822681
03
Conditions
psychosis
Beyond the preview
Go deeper on NL-OMON30850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30850.